Postpolycythemic and postthrombocythemic myeloid metaplasia are consensually referred
to as secondary myelofibrosis (sMF). Prognostic variables in sMF are not as well defined as …

Abstract BACKGROUND Approximately 30–50% of patients with myelofibrosis with myeloid
metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value …

Myelofibrosis with myeloid metaplasia (MMM) is an infrequent disease usually affecting
elderly people. Due to the lack of a specific marker for MMM, efforts are being made to refine …

Median survival of patients with myelofibrosis with myeloid metaplasia (MMM) ranges from
3.5 to 5 years, but there is a wide variability. The degree of anemia (Hb< 10 g/dL) is the most …

The prognostic importance of genetic information in primary myelofibrosis (PMF) was
recently highlighted in a study of over 1000 cytogenetically‐annotated patients; 5‐year …

Myelofibrosis with myeloid metaplasia (MMM) is an uncommon disorder in young
individuals, for whom haemopoietic stem cell transplantation offers the only possibility of …

Although cytogenetic abnormalities are important prognostic factors in myeloid
malignancies, they are not included in current prognostic scores for primary myelofibrosis …

BACKGROUND. Previous prognostic studies in primary myelofibrosis have focused on risk
factors for overall survival and have resulted in the establishment of several prognostic …

PURPOSE: Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative
disorder characterized by bone marrow fibrosis and extramedullary hematopoiesis. Recent …

BACKGROUND AND OBJECTIVES: The levels of circulating hematopoietic progenitor cells
are often increased in myelofibrosis with myeloid metaplasia (MMM). The prognostic …